Please login to the form below

Not currently logged in
Email:
Password:

Janssen/Jubilant alliance

Janssen Pharmaceutica and Jubilant Discovery Services have agreed a drug discovery partnership covering the field of neuroscience

Janssen Pharmaceutica and Jubilant Discovery Services have agreed a drug discovery partnership covering the field of neuroscience.

The alliance, which will see Jubliant develop preclinical drug clients for Janssen to develop and commercialise, is set to last at least three years.

Jubilant is to receive research funding and is eligible for future milestones and royalties depending on the success of drug candidates.

Financial terms were not disclosed.

"The collaboration will utilise Jubilant's global research network to include our new research facility in the US focused in the area of neuroscience, in addition to our India-based research centres," said Sri Mosur, CEO and president, global drug discovery and development, Jubilant.

"We look forward to enhancing the research and development efforts at Janssen through this unique and creative alliance in these dynamic times in the industry."

28th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics